Skip to content
CancerIndex

Publication

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.

Authors not recorded

Oncotarget2015PMID 26515464PMC4770737stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (8)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 8

Curated evidence

Evidence citing this paper (3)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
26515464
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
EGFR Exon 19 Deletion1
AfatinibLung Non-Small Cell CarcinomaCURATED_BROADERPredictiveDSupports Sensitivity Response2accepted
EID969

Cells harboring an exon 19 deletion were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to dir… (full text at CIViC)

PMID 26515464 · Hirano et al., 2015 · Open in CIViC

civic
EGFR L858R1
AfatinibLung Non-Small Cell CarcinomaCURATED_BROADERPredictiveDSupports Sensitivity Response2accepted
EID968

Cells harboring L858R were sensitive to afatinib. This study performed drug response assays using five human NSCLC cell lines with various combinations of EGFR mutations. In order to directly compare … (full text at CIViC)

PMID 26515464 · Hirano et al., 2015 · Open in CIViC

civic
EGFR T790M1
Osimertinib + RociletinibSubstitutesLung Non-Small Cell CarcinomaCURATED_BROADERPredictiveDSupports Sensitivity Response2accepted
EID967

For cells harboring EGFR T790M mutation, osimertinib and rociletinib showed potent inhibition compared to erlotinib or afatinib. This study performed drug response assays using five human NSCLC cell l… (full text at CIViC)

PMID 26515464 · Hirano et al., 2015 · Open in CIViC

civic